Zhenxin Wang1, Guoqing Zhang2, Zhongcheng Li3, Jin Li4, Hongbo Ma4, Ailian Hei4, Shunchang Jiao1, Yi Hu1, Shengjie Sun1, Liangliang Wu1, Ji Zhou4, Yu Wang5, Ellen He4, Sven Skog4. 1. Department of Oncology, Affiliated Hospital of Suzhou University, Shizi Street 188, Gusu District, Suzhou, China. 2. Department of Oncology, Peking 301 Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing 100853, China. 3. Department of Thoracic Surgery, Affiliated Hospital of Suzhou University, Shizi Street 188, Gusu District, Suzhou, China. 4. Department of Medicine, Shenzhen SSTK Precision Medicine Institute, A301, Building 1, 1301-76 Guanguang Road, Longhua District, Shenzhen, China. 5. Health Management Center of PLA 910 Hospital, Quanzhou 362000, Fujian, China.
Abstract
AIM: A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs). PATIENTS & METHODS: The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017. RESULTS: Kaplan-Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS. CONCLUSION: STK1p is helpful in predicting OS of early/middle stages (I-IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs.
AIM: A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs). PATIENTS & METHODS: The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017. RESULTS: Kaplan-Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS. CONCLUSION: STK1p is helpful in predicting OS of early/middle stages (I-IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs.